pdufa.bio
Home › Decisions › AZN 2026-05-15

AZN FDA decision — May 15, 2026

✓ APPROVED

AstraZeneca PLC — ENHERTU (trastuzumab deruxtecan) - (DESTINY- · High-Risk HER2 Positive Early-Stage Breast Cancer.

Run-up into the decision (T-120 → T+5)

PDUFA 5/15/26$209.48$177.3611/28/25
Daily close, T-120 (11/28/25) through T+5. Run-up high $209.48 on 2/18/26, low $177.36 on 11/28/25 (T-120 to T-1). FDA decision 5/15/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-05-15
OutcomeApproved
Drug / candidateENHERTU (trastuzumab deruxtecan) - (DESTINY-
CompanyAstraZeneca PLC
120-day run-up (T-120→T-1)+4.3%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio